FDA Commissioner Gottlieb Tenders Resignation

The above announcement comes on the heels of FDA Commissioner Gottlieb’s announcement last week that he is resigning effective in April, and the naming of Acting Commissioner, Dr. Ned Sharpless, who has until now served as Director of the National Cancer Institute.

Commissioner Gottlieb has been committed to addressing the issue of underage use of ENDS. This announcement of draft guidance just a week after his resignation indicates an ongoing commitment on his part to see this initiative through, as well as signaling to industry that the Acting Commissioner and the agency will continue Dr. Gottlieb’s work.